Kim Smith-Whitley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9769130/publications.pdf

Version: 2024-02-01

516710 395702 1,197 58 16 33 g-index citations h-index papers 63 63 63 1509 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood, 2016, 127, 17-28.	1.4	165
2	Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood, 2004, 103, 422-427.	1.4	131
3	Reducing Health Care Disparities in Sickle Cell Disease: A Review. Public Health Reports, 2019, 134, 599-607.	2.5	123
4	Clinical Outcomes Associated With Sickle Cell Trait. Annals of Internal Medicine, 2018, 169, 619.	3.9	78
5	Reproductive issues in sickle cell disease. Hematology American Society of Hematology Education Program, 2014, 2014, 418-424.	2.5	72
6	Reproductive issues in sickle cell disease. Blood, 2014, 124, 3538-3543.	1.4	67
7	A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood, 2015, 126, 1651-1657.	1.4	57
8	Community Health Workers as Support for Sickle Cell Care. American Journal of Preventive Medicine, 2016, 51, S87-S98.	3.0	57
9	Indications and complications of transfusions in sickle cell disease. Pediatric Blood and Cancer, 2012, 59, 358-364.	1.5	44
10	Complications in pregnant women with sickle cell disease. Hematology American Society of Hematology Education Program, 2019, 2019, 359-366.	2.5	42
11	Title is missing!. Journal of Clinical Psychology in Medical Settings, 2002, 9, 201-209.	1.4	36
12	Mistrust of Pediatric Sickle Cell Disease Clinical Trials Research. American Journal of Preventive Medicine, 2016, 51, S78-S86.	3.0	29
13	Determining the longitudinal validity and meaningful differences in HRQL of the PedsQLâ,,¢ Sickle Cell Disease Module. Health and Quality of Life Outcomes, 2017, 15, 124.	2.4	26
14	Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. British Journal of Haematology, 2021, 194, 970-979.	2.5	22
15	Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to $11 {\rm \AA}$ years. Pediatric Blood and Cancer, 2022, 69, e29716.	1.5	21
16	Development and Validation of the Youth Acute Pain Functional Ability Questionnaire (YAPFAQ). Journal of Pain, 2014, 15, 1319-1327.	1.4	18
17	Transfusion support of patients with sickle cell disease at the Children's Hospital of Philadelphia. Immunohematology, 2006, 22, 121-125.	0.2	18
18	Case Definitions for Conditions Identified by Newborn Screening Public Health Surveillance. International Journal of Neonatal Screening, 2018, 4, 16.	3.2	17

#	Article	IF	CITATIONS
19	Family Functioning, Medical Self-Management, and Health Outcomes Among School-Aged Children With Sickle Cell Disease: A Mediation Model. Journal of Pediatric Psychology, 2018, 43, 423-433.	2.1	14
20	Asymptomatic Factor VII Deficiency in African Americans. American Journal of Clinical Pathology, 2006, 126, 128-132.	0.7	13
21	Reproductive intentions in mothers of young children with sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28227.	1.5	12
22	Muscle Strength, Power, and Torque Deficits in Children With Type SS Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2018, 40, 348-354.	0.6	11
23	Effect of High-dose Vitamin A Supplementation in Children With Sickle Cell Disease: A Randomized, Double-blind, Dose-finding Pilot Study. Journal of Pediatric Hematology/Oncology, 2020, 42, 83-91.	0.6	11
24	Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies. Molecular Therapy, 2021, 29, 1625-1638.	8.2	10
25	Echocardiographic Screening of Cardiovascular Status in Pediatric Sickle Cell Disease. Pediatric Cardiology, 2019, 40, 1670-1678.	1.3	9
26	Contraceptive use and preferences among females with sickle cell disease. Contraception, 2022, 105, 42-45.	1.5	9
27	Adherence to prompt fever evaluation in children with sickle cell disease and the health belief model. Pediatric Blood and Cancer, 2015, 62, 1968-1973.	1.5	8
28	Parental Attitudes Towards Prenatal Genetic Testing For Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2019, 41, 579-585.	0.6	8
29	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
30	HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol. BMC Pediatrics, 2019, 19, 354.	1.7	7
31	The Cellie Coping Kit for sickle cell disease: Initial acceptability and feasibility Clinical Practice in Pediatric Psychology, 2014, 2, 389-399.	0.3	6
32	Splenic infarction in sickle cell trait: A comprehensive systematic review of case studies. EJHaem, 2021, 2, 585-600.	1.0	6
33	Benefit of pulmonary subspecialty care for children with sickle cell disease and asthma. Pediatric Pulmonology, 2022, 57, 885-893.	2.0	6
34	Inclusion of a short hairpin RNA targeting <i>BCL11A</i> into a \hat{l}^2 -globin expressing vector allows concurrent synthesis of curative adult and fetal hemoglobin. Haematologica, 2021, 106, 2740-2745.	3.5	5
35	Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies. Blood, 2019, 134, 991-991.	1.4	5
36	Understanding sickle cell disease: impact of surveillance and gaps in knowledge. Blood Advances, 2020, 4, 496-498.	5.2	4

3

#	Article	IF	CITATIONS
37	Reproductive Decisions in Families Affected By Sickle Cell Disease. Blood, 2014, 124, 2175-2175.	1.4	3
38	Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study. Blood, 2020, 136, 17-19.	1.4	2
39	An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. Blood, 2013, 122, 2206-2206.	1.4	2
40	Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID. Blood, 2013, 122, 330-330.	1.4	2
41	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. Blood, 2013, 122, 775-775.	1.4	2
42	A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in Children. Blood, 2014, 124, 88-88.	1.4	2
43	2'-O-methoxyethyl splice-switching oligos correct splicing from IVS2-745 \hat{l}^2 -thalassemia patient cells restoring HbA production and chain rebalance. Haematologica, 2021, 106, 1433-1442.	3.5	2
44	Iliopsoas hematoma in a patient with sickle cell disease. Pediatric Blood and Cancer, 2018, 65, e27040.	1.5	1
45	Swaying sickle cell research forward in support of patient reported outcomes. American Journal of Hematology, 2021, 96, 402-403.	4.1	1
46	Incidence of Hemolytic Events after Exposure to Triggering Medications in Pediatric Patients with G6PD Deficiency. Blood, 2016, 128, 4810-4810.	1.4	1
47	23 Years of Management: A Retrospective Review of Treatment for Aplastic Anemia Blood, 2009, 114, 1091-1091.	1.4	1
48	Preclinical Evaluation of ALS20, a New and Improved Lentiviral Vector for Beta-Globinopathies. Blood, 2019, 134, 2242-2242.	1.4	1
49	Discordant Beliefs, Perceptions, and Experiences between Patients with Sickle Cell Disease and Their Care Teams: Insights from a Pilot Program to Support Shared Decision-Making. Blood, 2020, 136, 15-17.	1.4	1
50	Mental health assessment of youth with sickle cell disease and their primary caregivers during the COVIDâ \in 19 pandemic. Pediatric Blood and Cancer, 0, , .	1.5	1
51	Transcranial Doppler ultrasonography in siblings with sickle cell disease. British Journal of Haematology, 2003, 121, 375-380.	2.5	0
52	Sickle Cell Disease, 2015. American Journal of Preventive Medicine, 2016, 51, S5-S9.	3.0	0
53	Hospitalization Rate and Regional Differences in Comprehensive Care in Transfused Patients with Sickle Cell Disease Compared to Thalassemia: A Report from the Multi-Center Study of Iron Overload Blood, 2005, 106, 3189-3189.	1.4	0
54	False Positive Pregnancy Test Resulting from Passive Transfusion of beta-Human Chorionic Gonadotropin (bHCG) from Donor Red Blood Cells Blood, 2006, 108, 4152-4152.	1.4	0

#	Article	IF	CITATIONS
55	A Pilot Study of Tapered Oral Dexamethasone for the Acute Chest Syndrome of Sickle Cell Disease Blood, 2009, 114, 1515-1515.	1.4	O
56	2'-O-Methoxyethyl Splice-Switching Oligos to Reverse Splicing from IVS2-745 \hat{l}^2 -Thalassemia Patient Cells: A Foundation for Potential Therapies. Blood, 2019, 134, 2244-2244.	1.4	0
57	Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell Disease. Blood, 2019, 134, 4713-4713.	1.4	O
58	National Survey of Pediatric Sickle Cell Providers on Their Contraceptive Practices for Female Patients. Blood, 2021, 138, 1898-1898.	1.4	0